Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.72 |
| ▸ | RAB9A | P51151 | 5/20 | 0.64 |
| ▸ | CA1 | P00915 | 2/20 | 0.62 |
| ▸ | CA2 | P00918 | 2/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.58 |
| ▸ | NPC1 | O15118 | 4/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | CA12 | O43570 | 1/20 | 0.53 |
| ▸ | CA7 | P43166 | 1/20 | 0.53 |
| ▸ | CA9 | Q16790 | 1/20 | 0.53 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.53 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.52 |
| ▸ | STS | P08842 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | BLM | P54132 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1881566 | 0.85 | MAPT (0.79) | MAPTRAB9ACA1CA2SMN1; SMN2 | |
| SCHEMBL1951546 | 0.84 | MAPT (1.00) | MAPTRAB9ACA1CA2SMN1; SMN2 | |
| SCHEMBL1794249 | 0.84 | MAPT (0.77) | MAPTRAB9ACA1CA2SMN1; SMN2 | |
| SCHEMBL10295156 | 0.82 | MAPT (0.75) | MAPTRAB9ACA1CA2SMN1; SMN2 | |
| SCHEMBL2469151 | 0.82 | MAPT (0.89) | MAPTRAB9ACA1CA2SMN1; SMN2 | |
| SCHEMBL204175 | 0.82 | MAPT (0.75) | MAPTRAB9ACA1CA2SMN1; SMN2 | |
| SCHEMBL4757010 | 0.81 | MAPT (0.72) | MAPTRAB9ACA1CA2SMN1; SMN2 | |
| SCHEMBL269377 | 0.81 | MAPT (0.72) | MAPTRAB9ACA1CA2SMN1; SMN2 | |
| SCHEMBL28814321 | 0.81 | MAPT (0.72) | MAPTRAB9ACA1CA2SMN1; SMN2 | |
| SCHEMBL7627879 | 0.81 | MAPT (0.72) | MAPTRAB9ACA1CA2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102762602-B | New internal and external donor compounds for olefin polymerization catalysts | BASF CORP | 2014-08-13 | — | — | CN | claimed |
| EP-3728234-B1 | RADIOLABELED COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2025-05-14 | — | — | EP | disclosed |
| US-11541132-B2 | Radiolabeled compounds | HOFFMANN-LA ROCHE INC. (US) | 2023-01-03 | — | — | US | disclosed |
| US-11541132-B2 | Radiolabeled compounds | HOFFMANN-LA ROCHE INC. (US) | 2023-01-03 | — | — | US | disclosed |
| EP-3728234-A1 | RADIOLABELED COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2020-10-28 | — | — | EP | disclosed |
| US-20200316232-A1 | RADIOLABELED COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2020-10-08 | — | — | US | disclosed |
| US-20200316232-A1 | RADIOLABELED COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2020-10-08 | — | — | US | disclosed |
| CN-111511732-A | Radiolabelled compounds | 豪夫迈·罗氏有限公司 | 2020-08-07 | — | — | CN | disclosed |
| CN-106065009-B | Application as the compound of hepatitis c inhibitor and its in drug | 广东东阳光药业有限公司 | 2019-03-01 | — | — | CN | disclosed |
| CN-108558889-A | Bu Luomo structural domain inhibitor | 赛尔基因昆蒂赛尔研究公司 | 2018-09-21 | — | — | CN | disclosed |
| CN-102762602-B | New internal and external donor compounds for olefin polymerization catalysts | BASF CORP | 2014-08-13 | — | — | CN | disclosed |
| CN-101423500-A | Substituted benzoxazoles and analogues as estrogenic agents | WYETH CORP (US) | 2009-05-06 | — | — | CN | disclosed |
| CN-100443477-C | Substituted benzo * oxazoles and analogs as estrogenic agents | WYETH CORP (US) | 2008-12-17 | — | — | CN | disclosed |
| CN-101044126-A | Prodrug substituted benzoxazoles as estrogenic agents | WYETH CORP (US) | 2007-09-26 | — | — | CN | disclosed |
| CN-1646504-A | Substituted benzoxazoles and analogs as estrogenic agents | WYETH CORP (US) | 2005-07-27 | — | — | CN | disclosed |
| EP-1070708-B1 | Triazole derivatives | HOFFMANN LA ROCHE (CH) | 2004-01-14 | — | — | EP | disclosed |
| US-6265426-B1 | CENTRAL NERVOUS SYSTEM DISORDERS | HOFFMANN-LA ROCHE INC. | 2001-07-24 | — | — | US | disclosed |
| EP-1070708-A1 | Triazole and imidazole derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2001-01-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11541132-B2 | Radiolabeled compounds | SNCA, APP, BACE1 | MAPT 16/4885RAB9A 163/4885CA1 2223/4885 |
| US-20200316232-A1 | RADIOLABELED COMPOUNDS | SNCA, APP, BACE1 | MAPT 17/4885RAB9A 160/4885CA1 2082/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.